GeoVax Positions Gedeptin as Immune-Sensitizing Platform Amid Industry Shift to In Vivo Cancer Therapies
GeoVax highlights its gene-directed enzyme prodrug therapy Gedeptin as a potential immune-sensitizing platform that could enhance checkpoint inhibitor efficacy in solid tumors, aligning with rising industry investment in simplified in vivo cancer treatments.
GeoVax Labs, Inc. (Nasdaq: GOVX) is positioning its oncology asset Gedeptin (Ad/PNP) as a strategic platform to address a key challenge in cancer immunotherapy: converting immunologically 'cold' tumors into 'hot' ones that respond to checkpoint inhibitors. The company's announcement comes amid a wave of industry investment in next-generation in vivo cancer therapies aimed at simplifying delivery and improving scalability.
Gedeptin is a gene-directed enzyme prodrug therapy (GDEPT) delivered intratumorally. It encodes purine nucleoside phosphorylase (PNP), which converts a systemically delivered prodrug into a cytotoxic agent directly within the tumor microenvironment. This localized approach is designed to destroy both proliferating and non-proliferating tumor cells while minimizing systemic toxicity. Notably, pre-clinical studies have shown that PNP treatment can be additive or synergistic with checkpoint blockade agents. In metastatic tumor models, treating a single lesion sensitized distant untreated tumors to checkpoint inhibitors, presumably by destroying tumor tissue, exposing neoantigens, and enhancing immune response.
David A. Dodd, Chairman and CEO of GeoVax, stated: 'While the industry is investing heavily in next-generation cell and gene therapies, the ability to positively modify the local tumor environment is believed to be one of the critical determinants of clinical success. Gedeptin is designed to directly destroy both proliferating and non-proliferating tumors, while also demonstrating high bystander activity due to the ability of the in situ generated cytotoxic agent to diffuse into neighboring tumor cells.'
GeoVax is advancing Gedeptin in combination with checkpoint inhibition in a planned Phase 2 clinical trial for first-line head and neck cancer, with additional solid tumor indications under evaluation. Kelly T. McKee, M.D., Chief Medical Officer, noted: 'Checkpoint inhibitors have transformed cancer care, but many patients still do not achieve durable responses. We believe Gedeptin is well positioned as a combination-enabling platform designed to enhance therapeutic response across checkpoint inhibitors and other emerging oncology modalities.'
Gedeptin has received Orphan Drug Designation for oral and pharyngeal cancers and has completed a multicenter Phase 1/2 clinical trial in advanced head and neck cancer. The company continues to evaluate strategic partnerships for its development and potential commercialization. For more information, visit GeoVax's website.